Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naloxone HCl intranasal Clear all
Terminated Phase 2 Interventional Results available

Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

NCT05114460
View directory record Official record
Conditions
Opioid Overdose
Interventions
Naloxone, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 27, 2026, 6:43 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg

NCT06719986
View directory record Official record
Conditions
Opioid Overdose
Interventions
Nalmefene HCl injection, Naloxone HCl intranasal
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone

NCT04764630
View directory record Official record
Conditions
Healthy Subjects, Opioid Antagonist, Pharmacokinetics
Interventions
Four naloxone nasal spray doses (1 every 2.5 min), Four naloxone nasal spray doses (2 every 2.5 min), Two naloxone nasal spray doses (1 every 2.5 min)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers

NCT02572089
View directory record Official record
Conditions
Drug Overdose, Opioid-Related Disorders
Interventions
Naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 27, 2026, 6:43 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Naltrexone for Overdose Prevention

NCT06633900
View directory record Official record
Conditions
Overdose Accidental
Interventions
IM naltrexone, Usual Care
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

NCT04851301
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions
Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history
Behavioral · Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Neural Correlates of Hypoalgesia Driven by Observation

NCT03897998
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo
Interventions
Naloxone, Saline
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Naloxone Pharmacokinetics

NCT03386591
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Naloxone, Mucosal atomization device and syringe, Narcan, Intramuscular Auto Injector
Drug · Device
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 27, 2026, 6:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Mobile Intervention for Young Opioid Users

NCT03610672
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
OD prevention/response training, OD prevention/response training + PI mobile application
Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years to 29 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Naloxone, Hypoglycemia and Exercise

NCT03149770
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Naloxone then placebo, Placebo then Naloxone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 27, 2026, 6:43 PM EDT
Not listed Not applicable Interventional

Improving Availability of Intranasal Naloxone

NCT05877118
View directory record Official record
Conditions
Opioid Overdose
Interventions
Enhanced Overdose Education (EOE), Standard education
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 27, 2026, 6:43 PM EDT
Not listed Phase 4 Interventional

Nasal Naloxone for Narcotic Overdose

NCT01912573
View directory record Official record
Conditions
Drug Overdose
Interventions
Intranasal (IN) naloxone, Intravenous (IV) naloxone, Intramuscular (IM) naloxone, Intraosseus (IO) naloxone
Drug
Lead sponsor
Judith Feinberg
Other
Eligibility
12 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Batavia, Ohio • Portsmouth, Ohio • West Union, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Usability Assessment of Naloxone Administration by Untrained Community Members

NCT04025671
View directory record Official record
Conditions
Harm Reduction, Opioid-use Disorder, Naloxone
Interventions
Nasal Spray Naloxone, Intramuscular Naloxone, Improvised Nasal Atomizer
Device
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Evaluation of Intranasal Nalmefene

NCT04828005
View directory record Official record
Conditions
Pharmacodynamic
Interventions
Nalmefene hydrochloride, Naloxone hydrochloride
Drug
Lead sponsor
Opiant Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone, Intravail
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

NCT05377255
View directory record Official record
Conditions
Opioid Overdose
Interventions
16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray
Combination Product
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose

NCT04129138
View directory record Official record
Conditions
Caregiver, Patient
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

NCT01760473
View directory record Official record
Conditions
Heroin Dependence
Interventions
Intranasal challenge drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 27, 2026, 6:43 PM EDT